Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's based on more than 15 years of trading stinky pinkies and how all the stories follow the same script. That's the REALITY.
Inevitable that the standard of accounting conducted by in house amateurs bumbling through it is not anywhere near what an auditor will allow
Further to that post, IF it ever gets done odds greatly favor there will be some not so subtle changes to what you have been led to believe in terms of the financial 'health' of $RXMD
If you are expecting the audit to be a positive event I'd reflect for a moment on all that could go wrong .. risk vs. reward not worth it I'd rather pay up for a stock on an up swing with good news confirmation then take my chances with this shaky binary MAYBE event.
I seem to remember all this audit talk 2 years ago ... at some point you just have to say enough is enough when companies flake out and have shady dealings that have decimated shareholders
Look for the first excuse on the audit delay because it is tax season and the auditor has a time crunch for other clients while this work has no deadline and can be done anytime
Then the discrepancies will become the next delay with auditor fired and search for a new one
The writing is on the wall (and the chart) to play out for the July .008 or less shares for the consolidated lender
Don't expect anything .. in the first place Ms. Mars don't speak to good and don't exactly inspire confidence
But worse, I would think in the interest of full disclosure the presentation includes red flag number one; the whole debacle with MV (excuses/controversy/law suits will not resonate well with 'new investors') as well as red flag number two; explaining they are a public traded company that hasn't bothered to audit the financials but "have plans to"
Truth is no one is at SeeThru except all the CEO's ..pretty sure they host it in a hallway and it's just all the CEO's lined up waiting for their turn to do a YouTube interview ... only people that ever view it are the posters on this board ...that's it .. sometimes it can get the desired hype if the chart has a good set up like last year but not going to happen with this chart this year
There are many resistance levels being left behind and the overhang of bag holders assures any rally will be sold so no need to cover more than .028 & .03
Supports are .018, .014. .01,
then .005 should be relatively strong if not .004 or .003 have held up very well in the past. Any of those are good loading zones and will be aligned with where the consolidated lender will be getting their shares which is always the best way to play a stinky pinky anyway if you can
$RXMD Weekly Chart
First thing that stands out is with a heavy float of 3hundredhowevermanywhoknows?MILLION is it seems to take a minimum of twice the volume per week compared to what we have been seeing this year in order to gain any upward traction
I suppose a big factor in that is how many new shares are entering the float on any given week. An example the week of Aug 29th saw decent volume of 15M+ yet the pps still only saw a range of .027 - .034
Regardless the lack of volume the past 6 months is the biggest factor resulting in the downward pressure we see in the stock .. share count is just too heavy(ierbytheday)
Every rally is just a lower high
10 Week MA crossed down over 50 Week MA 2 months ago (final kicker) and the 20 Week MA after leveling off for some sideways churn has now resumed it's path downward with the rest of the MA's
Can't see the 200 Week MA on this chart it was left behind currently up @ .056 and has not been touched since 2013 which was before the Popsicle stand took over this ticker
RSI has struggled to conquer let alone sustain 50 since June
MACD & OBV - one word - sadshape
ADX perking up but that indicator measures the strength of the trend ...with the red line on top what we have here a is a strengthening down trend
http://stockcharts.com/h-sc/ui?s=RXMD&p=W&yr=1&mn=0&dy=0&id=p29421446548&a=508583377
Cheers & GLTA!
Bull trap set yesterday ... today's tapering volume and yet another lower high confirm
Where are you BULLS? Don't you want these cheapies while they last? LOL
It's a pink sheet that's all the proof you need = flipping stock = that is just how they all play out same song and dance across the board none of these are for investing they are a vehicle for the companies to raise funding PERIOD ...NONE OF THEM HAVE ANY VALUE LONG TERM they are for TRADING ONLY
Are you going to cling to hope all the way until they announce the reverse split?
The writing is on the wall here it had it's day in the sun this is what happens to them when volume goes to the next one
Let's look at risk reward here
Say they get audit and 'up list' to QB ... nothing happens to pps
Audit gets delayed ...price down
Issues with audit ... price down
Auditors get fired .... price down
Yes the old 3 strikes and your out analogy
$RXMD on the pitching mound fixing the game
Auditors will be fired over discrepencies in Unaudited mess
This scheme is a set up to get the consolidated lender shares @ .008 or less as per filings
I don't understand how anyone can not see through See Thru - nothing more than a pump & dump sham
Never more evident than when they came out with a $1.52 TP on a .04 stock
Only costs a company $11K/year for a rudimentary Youtube interview & to retain their assistance in selling shares
When you see See Thru on the scene DO NOT make eye contact turn your back to them and run far away
SeeThruEquity claims to be “the first truly independent research provider in the capital markets” which is “commited to providing unbiased research for companies under $1 billion in market capitalization“. However it’s hard to see how this can be the case when you look at SeeThruEquity’s “Premier” services offering seen below:
Maybe today maybe tomorrow but the bottom is not in until it is .. this was coiling for weeks and could have gone either way but the clue even then was the constant rejection at the Weekly middle bollie 10 weeks in a row! that it would break down
Now below 100 Week MA and rejection on the back test confirms further down
Need a reason to be a buyer ya got one? Cuz it ain't on the chart
Not sure what your looking at everyone lowering their ASK today not to mention the thickening share count on that side while the bid side thins
Trendless meandering Daily lower high can't hold 10DMA ...any close below middle bollie @ .0265 REMAINS a BEAR BIAS
You do see the current price is BELOW the lower bollie on both the Daily & the Weekly right? Are we talking about the same ticker?
Sells vs. Buys 3 to 1
Nobody wants to buy ..fear has set in there is no reason to be long when that sentiment rules the day
Zero indication of reversal it has blown too many supports so I have no idea what your talking about ..wrong board??
Waterfall in progress the chart is completely broken
Only support left is lower bollie on the Monthly .0055 ..personally I don't trust it
Price below all supports does not make for a reversal
I'll let you know when it is safe to call a reversal ..won't be this week
POOF
Not to mention how many companies who are serial participants with See Thru have ever emerged a success story?
It's a complete farce to appease shareholders of unaudited pink sheet shams
Pretty telling they don't want their own stock ..it's a hot potato ...buyback maybe comes @ .005 but the pattern to date is they just selling stock so I have doubts
Widening spread very indicative of the short theory being the correct side to play on this ticker - .0192 will soon be .018 and once that gives way desperation will ensue ..count on .005 - it's a magnet on this chart
Ask stacking tell ETRF this won't see .028 we all know CDEL & NITE will stranglehold the low .02's until they are .01's and so on down we go
I think we will see more this week if not next.
HAHAHA thanks for that compliment but you wish .. was going to try and wait for .0292 to put on my short ..I'll be lucky to get .024
Chart here is burnt toast
We've all seen this movie before ...
Next news will be they fired the auditors because they wouldn't cook the books the way management wants them too
L2 looks awfully heavy and so far the tape =
57 500 Buys Vs. 366 110 Sells [licking my chops]
Nah I can't really go wrong here IF they actually do an audit there will be enough dirt turned up to add fuel to my shorts ... they got lotsa 'splaining to do voluntary audits never seem to work out the way anyone thought
It is evident many so called 'investors' here are giving up the ghost if that is the most exciting binary event you have incoming I'd get out of the way too lol
At some point you have to call uncle, draw the line and say enough is enough ..that point was 3 weeks ago imo
Good luck in all your trades!
They've been singing that song and dance and recycling that same PR for 2 years ..it's a ruse
RXMD is just in 1st gear in terms of potential and share price.
Let the fundamentals influence your decision on whether to invest, and the share price talk later which is the way u should prefer.
Hmmm just over a year ago there were nearly 100 000 000 less shares .. not sure how any other conclusion is reached other than the obvious FACT = DILUTION .. think the only (sort of) tangible you may have benefited - consultation for the website LOL
As of September 30, 2015, the total balance of shares issued and outstanding as reported by the transfer agent is
245,584,329 shares.
The chart tells the story really don't need to read filings to see the dilution occurring whether it is treasury, c/d's, shares issued for 'services' or probably all 3 but willing to bet the Nov. # is stale and growing. I mean honestly the chart is not even a gentle ski slope it has FALLEN OFF THE CLIFF!
I suggest you check on the filings yourself ...that is where the FACTS lie lol..yes the pun intended...convertible debt/shares issued for 'services' and the bottomless floor clauses that accompany them. Once the A/S is closer to maxed and the R/S announced will add fuel to the complete capitulation ...just the way it works on the UNAUDITED PINKS
Buy low sell high and then stay out of the way my friend ... think you are in the wrong lane on this one
The Company has identified conversion features embedded within the convertible debt issued on July 22, 2016. The
Company has determined that the conversion feature represents an embedded derivative. The conversion price is set at
$0.05 per share unless the Market Capitalization of the Company falls below $3,000,000 at which time the Lender’s
Conversion Price for all Lender Conversions occurring after the first date of such occurrence shall equal the lower of the
Lender Conversion Price and the Market Price as of any applicable date of Conversion. Accordingly, the embedded
conversion feature must be bifurcated from the debt host and accounted for as a derivative liability. On July 22, 2016,
the Company recorded a derivative liability in the amount of $80,696. For the period ended September 30, 2016, the
Company recorded a Change in Fair Value of the Derivative Liability in the amount of $41,354 with a Derivative Liability
on the Balance Sheet at September 30, 2016 of $122,050.
Can only enter there if the price reaches that .. say on a 'good'news day .. been a long time since I watched L2 which MM is it again CDEL or NITE that is the company diluting?
I see Float Bloat since I last checked that too
Used to be a long here stopped out many moons ago
If L2 looks heavy enough I may not have to wait for a pop
100% Agreed .19 is perfectly healthy retracement and middle bollie on the weekly ... this had huge move in a short time span and then held over the Upper Bollie on the weekly for 2 weeks ... Very healthy to put in a higher low here and builds strong support
.19 is middle bollie on weekly my bid is there to add but it may not get there
This had to consolidate after a triple bagger move in a 3 week span it may feel extreme but so was the move up .. then held nicely for 2 weeks UP AND OVER the UPPER BOLLIE on the WEEKLY!
This retracement is perfectly normal & healthy imo but U 2 go ahead & keep scaring everyone in to my bids ..thx
Congrats $ARIA
Our collaboration w/Pieris Pharmaceuticals $PIRS gets a nice shot in the arm with half of their market cap being paid cash up front to them, in a collaboration of their own with Servier, a pharmaceutical company headquartered in France....annual sales EUR4 Billion and 5 products to date in late pre-clinical or early development in immuno-oncology.
Under the collaboration, Pieris and Servier will initially pursue five bispecific therapeutic programs, led by Pieris' PRS-332 program, a potentially best-in-class PD-1-targeting bispecific checkpoint inhibitor.
No have not seen anything further .. I can only assume the 8K is enough to negate any concerns the company had abandoned the ticker
Certainly for me, it is evident we shall see further progress to this end and just hearing from them prompted me to add .003 same avg I paid on the prior freebies I still have ... will hold till they are gold or mold
Can't see them filing the 8K for no reason other than to finally advance the process of becoming public. (cleaning house/ticker change)
L2 had given clues lately that somebody wants shares here but I wasn't personally ready to pull the trigger on more until the silence broke
The writing is on the wall ...easy pickens is now I hate to chase. aimo
$HPTG
Here for roll call
Stop sign gone ... can now 'proceed with caution' LOL
http://www.otcmarkets.com/stock/HPTG/quote
OTC Markets along with our fraternity of longs giving the benefit of the doubt more filings/corporate action coming
$HPTG
Seems to me we are at the mercy of the BANDITS accumulating today at lower prices ... as others have said it does not take much AT ALL to push the price around
One indication of that is the larger sized buys hitting the tape are going off between the bid & ask... with weird denominations (3.8264, 3.8084)
Add to that just in the past hour the Buy vs. Sell in the vicinity of 14 to 1! How do I spell OBVIOUS??
http://ih.advfn.com/stock-market/NASDAQ/tapimmune-inc-TPIV/trades
Highway robbery to anyone selling imo $10+ will happen just as quick when the powers that be are ready
HERE for roll call :)... This is one select & legit penny I sleep well at night holding from .0175 almost 3 years now .. more recently added in the 3's up to .038
Any bids above .05 are getting took out but hopefully a good report will change that.
ah ha ...
The stock needs to trade above $4 for five trading days (end of trading on September 22nd) and the NASDAQ needs to approve the final application.
Join me in the celebration! ;)
http://livestream.com/nasdaq/live
$DMPI DelMar Pharmaceuticals ring the opening bell @ Nasdaq
The one time I did several months ago (Kevin Sarney handles IR) he was short & to the point referring me to filings/Pr's keeping cards held closely to their chest as one would expect.
They don't reveal much just yet even at conferences and the pps, albeit a bargain, may be stuck in this range for some time yet, but eventually we will hear more big player collaborations.
From the website:
We are leveraging the breadth of our technology through strategic collaborations. To date, we have engaged in several proof-of-concept collaborations with several leading pharmaceutical companies. Through them, our technology has been validated in a commercial setting, and a number of applications have been demonstrated.
Arthur has been President, Chief Executive Officer and a director since 2010. He has broad experience in the business and finance of healthcare enterprises and basic life sciences research. Prior to joining Enumeral, he was a partner in Ascent Biomedical Ventures, a life sciences venture capital firm focused on early-stage biomedical technologies, where he was responsible for originating and managing numerous biotechnology and medical device company investments from 2003 through 2009. Prior to venture capital, he served in the healthcare corporate finance and mergers and acquisitions group of Robertson Stephens. Before industry, he conducted research in lipid metabolism, genomics and cell biology as a Research Scientist at Columbia University from 1996 through 2000. He is a published author and inventor on a number of patents. He received his Ph.D. in molecular genetics from the Rockefeller University and his B.A. in biology from Grinnell College.
Welcome to the Nasdaq! - ringing the opening bell on Thursday the 14th
Congrats to DelMar & all longs
http://www.prnewswire.com/news-releases/delmar-pharmaceuticals-announces-approval-for-listing-on-nasdaq-300296399.html
Seems Mr. & Mrs. Market agree with you some nice size buys hit the tape this morning and twice the 30 day volume so far
Tis the season for M&A's ;) ... I think in general we will certainly see some ramping of that in the last half of '16 with the majority of bio's lowered valuations and the U.S. election looming the timing seems ripe ... we have not seen much of that go on for quite some time in this sector but we know all the BP's are shopping
I still hold hope the enormous potential for ENUM will survive on it's own for many years to come but I wouldn't complain if merger or acquisition is our fate ...I would venture a guess we would see 10X our investment from here very conservatively
As always, Thanks so much for bringing your perspective & knowledge here
And thanks for the pm I no longer have pm ... since February I have been going heavier in to the TSX as well as F/X ihub doesn't really cover those...the latter takes full focus so not using this site nearly as much as I used to ... still own all my U.S. Bio's + a few others and check in
Cheers & Happy 4th of July!
In terms of our current cash 'crunch', I have no worry whatsoever that something else is very near ....it may seem like the 11th hour to some and I too appreciate their candid verbiage in the Q (might even help to fill my bids) ;), but I have full confidence knowing Dr. Tinkelenberg's background. In addition to his PhD/Life Sciences Research, over the last decade or so he has actually been primarily involved with Healthcare Investment Banking/Mergers/Acquisitions
I know I am repeating myself and that you know this RK but for new visitors I submit that Dr. Tinkelenberg is a master of negotiations:
Quote:
Dr. Arthur H. Tinkelenberg, also known as Art, Ph.D., is a Co-Founder of Enumeral Biomedical Holdings, Inc. and has been its President and Chief Executive Officer since July 31, 2014. Prior to co-founding and leading Enumeral, Dr. Tinkelenberg was a Venture Partner of Ascent BioMedical Ventures (ABV). At Ascent Biomedical Ventures, he was responsible for originating and managing numerous biotechnology and medical device company investments from 2003 to 2009. Prior to joining ABV, he worked in the Healthcare Investment Banking and Mergers and Acquisitions Groups at Robertson Stephens from January 2001 to July 2002, where he advised clients on strategic and financing alternatives and participated in over $250 million in public, private, and merger transactions for biotechnology, medical device, and diagnostics companies. Dr. Tinkelenberg served as President and Chief Executive Officer of Enumeral Biomedical Corporation since 2010. He has broad experience in the business and finance of healthcare enterprises and basic life sciences research. Prior to industry, he conducted research in lipid metabolism, genomics, biochemistry, and cell biology as a Research Scientist at Columbia University from 1996 to 2000. Dr. Tinkelenberg has been a Director of Enumeral Biomedical Holdings, Inc. since July 31, 2014. He serves as a Director of Crosstrees Medical, Inc. and Ouroboros. He is a Board Observer for Azevan Pharmaceuticals, Metronome Therapeutics, and Vivios Pharmaceuticals. He served as a Director of Enumeral Biomedical Corporation since 2010. He served as a Director of Xlumena, Inc. He is a published author and inventor on a number of patents from projects initiated by him during his tenure in academic research. Dr. Tinkelenberg earned his Ph.D. degree in Molecular Genetics from The Rockefeller University where he studied cell growth regulation and signal transduction as a Rockefeller and National Science Foundation Fellow and earned his BA degree in Biology, with honors, from Grinnell College.
IMO, Pieris got a bargain on the one hand to get our "licensing & royalty MACHINE" rolling, (using your quote, I love that one), but in the other is the NON-exclusive component that leaves the door wide open for potential similar deals.
...and especially too with TIM-3 still in the offing where we evidently should really excel in this new age of research.
I don't find it unusual at all that he waits to play his cards for the best outcome in the longer run for the company .. I think he could pull the trigger on more non-dilutive financing any time he wants and thus is courting all the options fastidiously.
All in my own opinion which was substantiated for me the day I watched this presentation ...note the second last answer he gives in the Q&A is never more pertinent than now and bodes very well for Enumeral's innovations with BP suitors http://noble.mediasite.com/mediasite/Play/5355702bbd66458b989daa6759bc54071d?catalog=3a734bfc-b7b0-4496-95ea-5193c0db8116
PIRS Conference call has some interesting tidbits regarding the licensing agreement and their intent with it going forward ... the Q & A at the end reveals a little further color
http://seekingalpha.com/article/3974584-pieris-pharmaceuticals-pirs-ceo-stephen-yoder-q1-2016-results-earnings-call-transcript
"Our key objectives for 2016 are several and include the completion of our first-in-patient trial for PRS-080 in anemia, which is a prerequisite for establishing proof of concept in our targeted anemia patient population. It also includes continued progress for both PRS-060 in asthma and PRS-343 in HER2 solid tumors, with an anticipated initiation of first-in-man trials for each program in the first half of 2017; continued progress with our immuno-oncology multi-specifics franchise in general, including PRS-342 , working towards developing yet novel therapies with meaningful differentiation over conventional antibody approaches; also includes leveraging our licensing agreement with Enumeral to develop novel PD1-based multi-specific checkpoint blockade offering differentiation over current PD1 antibody approaches, and finally, potentially securing additional partnerships as further validation of our Anticalin drug platform."
From page 6 quotes from PIRS CEO Stephen Yoder:
"With respect to the Enumeral transaction, at the heart of this agreement is our fundamental belief that having an Anticalin antibody-based approach in the PD1 space is something that is very important to have a high value long-term immuno-oncology pipeline."
"So fundamentally, this is about having a best-in-class, potentially multiple best-in-class PD-based approaches, and we’ve already built multiple permutations of PD1 antibody Anticalin fusions with undisclosed but existing Anticalins in the checkpoint space."
Crazy low Market Cap here ... equivilent to about one Q of revs! Share structure updated yesterday I don't think it's changed any - this tiny float is known to explode this went to .90 intraday not long ago
ZERO dilution here EVER ...PPS should be .50 minimum
ASAE Security Details
Share Structure
Market Value1 $388,580 a/o Apr 26, 2016
Authorized Shares 45,000,000 a/o Apr 25, 2016
Outstanding Shares 14,445,363 a/o Apr 25, 2016
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 6,180,354 a/o Apr 25, 2016
Par Value 0.001
Transfer Agent(s)
Island Stock Transfer
Shareholders
Shareholders of Record 139 a/o Apr 25, 2016
Short Selling Data
Short Interest 0 (-100%)
Jul 15, 2015
Significant Failures to Deliver No
http://www.otcmarkets.com/stock/ASAE/profile
Wow that was easy! 2.28!! Had to close my position for now but enjoy the gap you boys & girls should get in the morn!
My bad, I had only a passing glance at that paper since I don't decipher those well enough plus my attention that morning was on F/X I didn't have time to vet (which is surface scratching at best) and just assumed it was new ... was unaware it was the exact same one my apologies.
I had noticed that verbiage in the 10K re:lung & Merck - and then the subsequent 8K ...I doubt pps will sit stale much longer as the clues are coming to light and more eyes arrive ....the non-exclusive w/PIRS also leaves the door wide open for much more to come
I am green as of Friday despite starting my Oct/Nov buys @.30 and some high 20's .... I'd be even happier to average up (as opposed to down but ready to do that more too IF it presents)